Literature DB >> 21251129

Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.

Jean-Philippe Couderc1, Christine Garnett, Mike Li, Robert Handzel, Scott McNitt, Xiajuan Xia, Slava Polonsky, Wojciech Zareba.   

Abstract

Thorough QT (TQT) studies are designed to evaluate potential effect of a novel drug on the ventricular repolarization process of the heart using QTc prolongation as a surrogate marker for torsades de pointes. The current process to measure the QT intervals from the thousands of electrocardiograms is lengthy and expensive. In this study, we propose a validation of a highly automatic-QT interval measurement (HA-QT) method. We applied a HA-QT method to the data from 7 TQT studies. We investigated both the placebo and baseline-adjusted QTc interval prolongation induced by moxifloxacin (positive control drug) at the time of expected peak concentration. The comparative analysis evaluated the time course of moxifloxacin-induced QTc prolongation in one study as well. The absolute HA-QT data were longer than the FDA-approved QTc data. This trend was not different between ECGs from the moxifloxacin and placebo arms: 9.6 ± 24 ms on drug and 9.8 ± 25 ms on placebo. The difference between methods vanished when comparing the placebo-baseline-adjusted QTc prolongation (1.4 ± 2.8 ms, P = 0.4). The differences in precision between the HA-QT and the FDA-approved measurements were not statistically different from zero: 0.1 ± 0.1 ms (P = 0.7). Also, the time course of the moxifloxacin-induced QTc prolongation adjusted for placebo was not statistically different between measurements methods. ©2011, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251129      PMCID: PMC3076006          DOI: 10.1111/j.1542-474X.2010.00402.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  42 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Problems of heart rate correction in assessment of drug-induced QT interval prolongation.

Authors:  M Malik
Journal:  J Cardiovasc Electrophysiol       Date:  2001-04

3.  Effects of three fluoroquinolones on QT interval in healthy adults after single doses.

Authors:  Gary J Noel; Jaya Natarajan; Shuchean Chien; Thomas L Hunt; Daniel B Goodman; Robert Abels
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

Review 4.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

5.  PC-Based ECG waveform recognition-validation of novel software against a reference ECG database.

Authors:  Corina-Dana Dota; Nils Edvardsson; Bo Skallefell; Gunnar Fager
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

6.  Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects.

Authors:  N B McLaughlin; R W Campbell; A Murray
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

7.  Automatic analysis of cardiac repolarization morphology using Gaussian mesa function modeling.

Authors:  Fabio Badilini; Martino Vaglio; Rémi Dubois; Pierre Roussel; Nenad Sarapa; Isabelle Denjoy; Fabrice Extramiana; Pierre Maison-Blanche
Journal:  J Electrocardiol       Date:  2008 Nov-Dec       Impact factor: 1.438

8.  Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

Authors:  Dagmar Kubitza; Wolfgang Mueck; Michael Becka
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

Authors:  M Iwamoto; J T Kost; G C Mistry; L A Wenning; S A Breidinger; T C Marbury; J A Stone; K M Gottesdiener; D M Bloomfield; J A Wagner
Journal:  J Clin Pharmacol       Date:  2008-04-25       Impact factor: 3.126

10.  Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.

Authors:  John D Davis; Frances Hackman; Gary Layton; Tracy Higgins; David Sudworth; Georges Weissgerber
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

View more
  10 in total

Review 1.  Clinical applications of QT/RR hysteresis assessment: A systematic review.

Authors:  Hugo Gravel; Vincent Jacquemet; Nagib Dahdah; Daniel Curnier
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-10-30       Impact factor: 1.468

2.  Man versus Machine: Comparison of Automated and Manual Methodologies for Measuring the QTc Interval: A Prospective Study.

Authors:  Jean T Barbey; Margaret Connolly; Brenda Beaty; Mori J Krantz
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-05-04       Impact factor: 1.468

3.  Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect.

Authors:  Karin Meiser; Pierre Jordaan; Sasha Latypova; Borje Darpo
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-12-19       Impact factor: 1.468

4.  Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.

Authors:  Borje Darpo; Georg Ferber; Meijian Zhou; Mark Sumeray; Philip Sager
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-30       Impact factor: 1.468

5.  The QT Scale: A Weight Scale Measuring the QTc Interval.

Authors:  Jean-Philippe Couderc; Connor Beshaw; Xiaodan Niu; Ernesto Serrano-Finetti; Oscar Casas; Ramon Pallas-Areny; Spencer Rosero; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-07-15       Impact factor: 1.468

6.  T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.

Authors:  Jean-Philippe Couderc; Xiajuan Xia; Derick R Peterson; Scott McNitt; Hongwei Zhao; Slava Polonsky; Arthur J Moss; Wojciech Zareba
Journal:  Heart Rhythm       Date:  2011-02-09       Impact factor: 6.343

7.  Use of ECG restitution (beat-to-beat QT-TQ interval analysis) to assess arrhythmogenic risk of QTc prolongation with guanfacine.

Authors:  Anthony A Fossa; Meijian Zhou; Antoine Robinson; Jaideep Purkayastha; Patrick Martin
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-09       Impact factor: 1.468

8.  The application of root mean square electrocardiography (RMS ECG) for the detection of acquired and congenital long QT syndrome.

Authors:  Robert L Lux; Christopher Todd Sower; Nancy Allen; Susan P Etheridge; Martin Tristani-Firouzi; Elizabeth V Saarel
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

9.  Genotype- and Sex-Specific QT-RR Relationship in the Type-1 Long-QT Syndrome.

Authors:  Jean-Philippe Couderc; Xiaojuan Xia; Isabelle Denjoy; Fabrice Extramiana; Pierre Maison-Blanche; Arthur J Moss; Wojciech Zareba; Coeli M Lopes
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

10.  Evaluation of differences in automated QT/QTc measurements between Fukuda Denshi and Nihon Koden systems.

Authors:  Motoaki Sano; Yoshiyasu Aizawa; Yoshinori Katsumata; Nobuhiro Nishiyama; Seiji Takatsuki; Shigeo Kamitsuji; Naoyuki Kamatani; Keiichi Fukuda
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.